Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

Background ANV419 is a stable antibody–cytokine fusion protein consisting of interleukin-2 (IL-2) fused to an anti-IL-2 monoclonal antibody that sterically hinders binding of IL-2 to the α subunit of its receptor but has selective affinity for the receptor βγ subunits. Thus, ANV419 preferentially st...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Markus Joerger, Emiliano Calvo, Heinz Läubli, Juanita Lopez, Elena Garralda, Dagmar Hess, Elena Corral de la Fuente, Christoph Bucher, Guzman Alonso, Sangeeta Jethwa, David König, Vicky Sanchez Perez
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMJ Publishing Group 2023-11-01
Saila:	Journal for ImmunoTherapy of Cancer
Sarrera elektronikoa:	https://jitc.bmj.com/content/11/11/e007784.full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!